Levosimendan Altan (Levosimendan)

Levosimendan increases the sensitivity of cardiac troponin C to calcium, which enhances myocardial contractility without raising intracellular calcium levels. It also opens ATP‑sensitive potassium channels in vascular smooth muscle, producing vasodilation and lowering afterload.

The dosing regimen for Levosimendan Altan is determined by the prescribing clinician based on the patient’s clinical condition, weight, and response. The prescriber will set the infusion rate and duration according to established guidelines and individual needs.

Safety data for levosimendan in pregnancy and lactation are limited. The product is classified as having an unknown pregnancy category, and it should be used only if the potential benefit justifies the potential risk to the fetus or infant.

To order Levosimendan Altan, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and import documentation.

Levosimendan differs from traditional inotropes such as dobutamine by sensitizing the heart to calcium rather than increasing intracellular calcium, which may reduce the risk of arrhythmias. It also provides vasodilatory effects, whereas dobutamine primarily increases heart rate and contractility without significant vasodilation.

Levosimendan Altan should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the solution. Keep the product in its original packaging until use to maintain stability.

Levosimendan Altan is given as an intravenous infusion. The solution is administered through a controlled IV pump, with the infusion rate adjusted by the healthcare professional according to the patient’s hemodynamic response.

Serious risks include severe hypotension, ventricular arrhythmias, myocardial ischemia, anaphylactic reactions, and significant liver enzyme elevation. Patients should be closely monitored for blood pressure changes, cardiac rhythm disturbances, and signs of allergic response during therapy.

Levosimendan is contraindicated in patients with known hypersensitivity to the drug, severe hypotension, or those receiving other potent vasodilators that could cause dangerous blood pressure drops. Caution is also advised in patients with severe renal or hepatic impairment.